The global clear aligners market is valued at $11.23 billion in 2026 and is expected to grow to $99.44 billion by 2034, expanding at a 31.34% CAGR. North America leads the market while Asia Pacific shows the fastest growth. Adults dominate by age segment, polyurethane leads by material type, and online distribution channels are expected to grow fastest. Key drivers include rising demand for aesthetic orthodontic solutions, technological advancements in 3D imaging and AI, and expanding access through digital platforms.

The global invisible orthodontics market is projected to grow from USD 9.91 billion in 2025 to USD 96.27 billion by 2034, expanding at a CAGR of 28.54%. Clear aligners dominate the product segment, with North America leading regionally and Asia-Pacific showing significant growth potential. Adults currently represent the largest age segment, while the teens segment is expected to grow rapidly. Key drivers include rising dental misalignment cases, technological advancements in 3D printing, and increased consumer awareness of aesthetic dental solutions.

A comprehensive market report on the U.S. Personal Protective Equipment market covering gowns, masks, face shields, gloves and other segments through 2033. The report provides revenue, volume, and pricing data across market segments with company share information for 2024, identifying key opportunities for market entry, expansion, and investment strategies.

The global sleeping bruxism treatment market is projected to grow from USD 652.14 million in 2025 to USD 1,132.09 million by 2033, expanding at a 7.18% CAGR. Growth is driven by rising awareness of sleep disorders, increasing stress levels, and demand for oral appliances and behavioral therapies. Occlusal splints and night guards dominate the market, while biofeedback therapy devices represent the fastest-growing segment. North America leads with 40% market share, while Asia Pacific is expected to grow fastest at 9.25% CAGR.

Zuckerman Investment Group increased its Henry Schein stake by 72,040 shares in Q3, bringing its position to 281,339 shares valued at $18.67 million. The purchase reflects confidence in Henry Schein's improving fundamentals, including 5% revenue growth to $3.3 billion, 13% non-GAAP EPS growth to $1.38, and a new $200 million efficiency plan. The company also repurchased $229 million in stock during the quarter.

Entrepreneur William Brooke Webb Jr. alleges that Henry Schein employee secretly opened a competing lab and sabotaged his business, leading to a two-volume book exposing corruption in the Oklahoma medical laboratory industry.

Henry Schein reported strong Q3 earnings, beating consensus estimates with $1.38 adjusted earnings per share and $3.34 billion in sales. The company expanded its strategic partnership with KKR and raised its fiscal 2025 guidance for earnings and sales.

Healthcare solutions distributor Henry Schein reported Q2 2025 financial results with mixed performance, experiencing revenue growth but declining profitability due to margin pressures in dental operations and increased restructuring costs.

The dental consumables market is expected to grow significantly, driven by factors like technological advancements, aging population, and rising demand for cosmetic dentistry. The U.S. is a key market, and the CAD/CAM devices segment is projected to experience the fastest growth.

Henry Schein reported mixed Q1 earnings, with adjusted EPS beating estimates but sales missing. The CEO expressed confidence in the company's business fundamentals and ongoing strategic initiatives.

U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.

Henry Schein reported Q4 earnings and outlook that missed expectations, but the company is restructuring for future growth. The company's 2025 guidance projects adjusted EPS and sales growth below consensus estimates.